^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    TRAF3IP2-AS1 (TRAF3IP2 Antisense RNA 1)

    i
    Other names: TRAF3IP2-AS1, TRAF3IP2 Antisense RNA 1, BetaFAAR, C6UAS, TRAF3IP2 Antisense RNA 2 (Non-Protein Coding), TRAF3IP2 Antisense RNA 1 (Non-Protein Coding), Beta-Cell Function And Apoptosis Regulator, TRAF3IP2-AS2, NCRNA00248, C6orf3, Chromosome 6 Open Reading Frame 3, Non-Protein Coding RNA 248, NONHSAG044611.2, HSALNG0052788, HSALNG0052787, TRAF3IP2-AS1
    Associations

    News

    Trials
    5ms
    Long Non-Coding RNAs in Psoriasis: A Comprehensive Review of Expression Profiles, Mechanistic Insights, Genetic Associations, and Their Clinical Implications. (PubMed, Noncoding RNA)
    The complex regulatory networks involving lncRNAs provide new insights into psoriasis pathogenesis and offer promising avenues for personalized treatment strategies. Integration of lncRNA profiling into clinical practice may enhance our understanding of disease heterogeneity and improve therapeutic outcomes for psoriatic patients.
    Review • Journal
    |
    CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • STAT3 (Signal Transducer And Activator Of Transcription 3) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) • HOTAIR (HOX Transcript Antisense RNA) • MEG3 (Maternally Expressed 3) • MIR31HG (MIR31 Host Gene) • XIST (X Inactive Specific Transcript) • TRAF3IP2-AS1 (TRAF3IP2 Antisense RNA 1)
    8ms
    TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis. (PubMed, Cancer Res)
    The elevated production of TGFβ1 created a feedback loop that promoted the transcription of TRAF3IP2-AS1 in tumor cells to balance necroptosis. Overall, these findings identify TRAF3IP2-AS1 as a key regulator of necroptosis and the formation of an immunosuppressive microenvironment in PDAC, providing potential therapeutic targets for treating liver metastasis in patients with pancreatic cancer.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1) • PPM1B (Protein Phosphatase, Mg2+/Mn2+ Dependent 1B) • IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2) • TRAF3IP2-AS1 (TRAF3IP2 Antisense RNA 1)
    9ms
    Downregulated TRAF3IP2-AS1 promotes hepatocellular carcinoma progression through the miR-374a-5p/SEL1L1/RPL6 axis to enhance DNA damage repair. (PubMed, Am J Transl Res)
    TRAF3IP2-AS1/miR-374a-5p/SEL1L/RPL6 pathway in HCC cells promoted DDR and HCC progression. Our data identify the role and mechanism of TRAF3IP2-AS1 in HCC and imply treatment targets for HCC.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • MIR374A (MicroRNA 374a) • TRAF3IP2-AS1 (TRAF3IP2 Antisense RNA 1)
    1year
    Disulfidptosis classification of pancreatic carcinoma reveals correlation with clinical prognosis and immune profile. (PubMed, Hereditas)
    Our proposed 3-DRLs-based feature could serve as a promising tool for predicting the prognosis, immune landscape, and treatment response of PC patients, thus facilitating optimal clinical decision-making.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • TRAF3IP2-AS1 (TRAF3IP2 Antisense RNA 1)
    |
    TMB-H • TMB-L
    2years
    Oncogenic lncRNA FAM215A promotes the malignant cell phenotypes of acute myeloid leukemia (AML) cell lines. (PubMed, J Mol Histol)
    Conclusively, FAM215A serves as an oncogenic lncRNA in AML, promoting cell viability, relieving cell cycle arrest, and suppressing cell apoptosis. FAM215A might be un underlying biological prognostic marker and therapeutic target for AML.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • E2F3 (E2F transcription factor 3) • MIR181A1 (MicroRNA 181a-1) • TRAF3IP2-AS1 (TRAF3IP2 Antisense RNA 1)
    2years
    Comprehensive analysis of cuproptosis-associated LncRNAs predictive value and related CeRNA network in acute myeloid leukemia. (PubMed, Heliyon)
    The risk signature established in this study could serve as a reliable biosignature for AML prognosis. And the findings presented here may facilitate research on cuproptosis in AML.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • TRAF3IP2-AS1 (TRAF3IP2 Antisense RNA 1)
    over2years
    Construction and validation of an NAD + metabolism-related lncRNA signature for predicting the prognosis and immune landscape of acute myeloid leukemia. (PubMed, Hematology)
    Enriched biological functions included leukocyte migration and positive regulation of cytokine production. The NAD metabolism-related lncRNA signature shows promise in predicting clinical outcomes for AML patients.
    Journal • Tumor mutational burden • IO biomarker
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • TRAF3IP2-AS1 (TRAF3IP2 Antisense RNA 1)
    |
    TP53 mutation